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Pan Kee Bae and Bong Hyun Chung*Abstract
The effective targeting of cancer cell surface antigens is an attractive approach in cancer diagnosis and therapy.
Multifunctional nanoprobes with cell-targeting specificity are likely to find important applications in bioanalysis,
biomedicine, and clinical diagnosis. In this study, we have fabricated biocompatible perfluorocan/quantum dot
nanoemulsions as bimodal imaging nanoprobes for the targeting of breast cancer cells. Perfluorocarbon/quantum
dot nanoemulsions conjugated with monoclonal antibodies, as a type of bimodal imaging nanoprobe based on
19 F-MR and optical imaging, have been synthesized and applied for targeted imaging of three different breast
cancer cells (SKBR3, MCF-7, MDA-MB 468), respectively. We have shown that the cancer-detection capabilities of
antibody-conjugated PFC/QDs nanoemulsions could be successfully applied to target of various breast cancer
cells. These modified PFC/QDs nanoemulsions were shown to target the cancer cell surface receptors specially.
Conjugation of ligands to nanoemulsions targeting over-expressed cell surface receptors is a promising
approach for targeted imaging to tumor cells. We further propose that the PFC/QDs nanoemulsions could be
used in targeted imaging of breast cancer cells.
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Medical imaging technologies have undergone explosive
growth over the past few decades and now play a central
role in clinical oncology. Targeted magnetic resonance
imaging (MRI) has emerged as a promising diagnostic
approach offering high resolution depictions of patho-
logical anatomy and the detection of associated disease
biomarkers [1-3]. Semiconductor quantum dots (QD) or
organic fluorophores as luminescence probes for many
biological and biomedical applications have long been
used to visualize cell biology at many levels, from mole-
cules to complete organisms [4-8]. Biologically bifunc-
tional nanoparticles with unique MR and optical imaging
capabilities are emerging as useful probes for biolabeling,
tumour-targeting, disease diagnosis, cell-based therapy,
targeted molecular imaging, optical sensing and biosen-
sors, drug delivery, and the monitoring of therapeutic ef-
fects [9-13]. The multimodal imaging will allow clinicians* Correspondence: chungbh@kribb.re.kr
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in any medium, provided the original work is pto not only see where a tumour is located in the body, but
also to visualize the expression and activity of specific
molecules and biological processes that influence tumour
behaviour and/or response to therapy.
Recently, many research groups in the world have
made every effort to synthesize the nanoparticles that
possess both fluorescent and magnetic properties. The
combination of fluorescent and magnetic properties is a
powerful tool allowing manipulation by magnetic fields
and visualization/detection by fluorescence. The per-
fluorocarbon (PFC) has been explored for various med-
ical applications, including liquid lung ventilation [14],
gastrointestinal contrast agent [15], and blood substitutes
[16,17]. PFCs are a class of molecules that are highly use-
ful for intracellular MRI tracer applications. While the 19 F
isotope of fluorine has a natural abundance of near 100%,
the biological presence is virtually zero. Therefore, the 19 F
molecule in PFC nanoemulsions has excellent properties
for MR spectroscopy and imaging without a surrounding
signal from endogenous fluorine [18-20]. Because of their
size-tunable emission spectra, broad absorption spectra,is an open access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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and chemical degradation, QDs are currently being inves-
tigated for many biological and biomedical applications as
luminescence probes [21-25].
In this context, we developed the fabrication of PFC/QD
nanoemulsions as bimodal imaging nanoprobes for the
targeting of breast cancer cells. Also, we have shown that
the cancer-detection capabilities of antibody-conjugated
PFC/QD nanoemulsions could be successfully applied to
target of various breast cancer cells. We further propose
that the PFC/QD nanoemulsions could be used in tar-





diphenyltetrazolium bromide (MTT), and cholesterol
were supplied by Sigma-Aldrich (St. Louis, MO).
Perfluoro-15-crown ether (PFCE) was purchased from
SynQuest Laboratories (Alachua, FL). 3-(N-succinimidylox-
yglutaryl) aminopropyl polyethyleneglycol-carbamyldistearoyl
phosphatidyl-ethanolamine (DSPE-PEG3400-NHS) was
supplied by NOF Co. (Tokyo, Japan) and CdSe/ZnS
QDs was obtained from Evident Technologies (Troy, NY).
L-α-phosphatidylcholine (lecithin, 95%, chicken egg) was
purchased from Avanti Polar Lipids (Alabaster, AL). Anti-
bodies were from following sources: anti-human EGF1R
(AbD serotec, Oxford, UK), anti-human ErbB2 and anti-
human IGF1R (R&D Systems, Inc., Minneapolis, MN). All
compounds for the cell culture were supplied by Invitrogen
(Carlsbad, CA).
2.2. Preparation of PFC/QD nanoemulsions
To fabricate PFC/QD nanoemulsions, two PFC materials
[PFCE and PFOB] and two different colored QDs (emit-
ting at 525, 606 nm) were used. For conventional hydro-
phobic ligand-capped CdSe/ZnS QDs to be compatible
with PFC liquids, the hydrophobic ligands of QDs
should be exchanged with PFDT. A 7 mg CdSe/ZnS
QDs dispersed in toluene was mixed with 34 g PFC liq-
uids containing 1 ml PFOT and methanol. After vigor-
ous mixing of the two-phase solutions for 24 h, the
CdSe/ZnS QDs were partitioned into the PFC phase.
The QDs in PFC were then washed three times with
methanol to remove the excess ligands from the solution.
The PFC liquids containing CdSe/ZnS QDs were emulsified
in an aqueous solution using surfactant mixtures. A surfac-
tant mixture composed of 78.5 mol% lecithin, 20 mol
% cholesterol, and 1.5 mol% DSPE-PEG3400-NHS were
dissolved in chloroform, and the organic solvent was
evaporated using a rotary evaporator and a freezing dryer
for 24 h. After dispersing the surfactant mixture into ster-
ilized distilled water, the solution was sonicated. PFC/QDsolution (40% v/v), the surfactant mixture (2% w/v) and
phosphate buffered saline were mixed for 4 min using a
homogenizer. The mixture was followed by microflui-
dization. A Microfluidizer M-110S (Microfluidics, Inc.,
Newton, MA) operating at a liquid pressure of approxi-
mately 20000 psi was used for all reported nanoemulsion
preparations. The fabricated PFC/QDs nanoemulsions
were separated using the size-exclusion column and were
stored at 4°C.
2.3. Preparation of antibody conjugated PFC/QD
nanoemulsions
For targeting the breast cancer cells, three different
antibodies [anti-human EGF1R, anti-human ErbB2 and
anti-human IGF1R] were conjugated to the PFC/QD
nanoemulsions. Antibody-conjugated PFC/QD nanoemul-
sions were developed by linking the carboxyl groups on the
surface of PFC/QD nanoemulsions with the amine groups
in antibodies. To the solution containing PFC/QD nanoe-
mulsions and antibodies, 1-ethyl-3-(3-dimethylamino pro-
pyl)carbodiimide (EDC) was added and permitted to react
with the NHS ligand of PFC/QD nanoemulsions for 2 h
at room temperature. To quench the reaction, add 2-
mercaptoethanol to a final concentration of 10 mM. The
antibody-coated PFC/QDs nanoemulsions were purified
by size-exclusion with sepharose 4B column and concen-
trated using ultrafiltration for 30 min.
2.4. Characterization of PFC/QD nanoemulsions
The emission spectra of PFC/QD nanoemulsions were
measured using a fluorescence spectrometer (LS 55,
PerkinElmer Instruments, Wellesley, MA). The mean par-
ticle diameters and zeta (ζ)-potentials of the PFC/QD
nanoemulsions were determined using a particle size
analyzer (ELS-Z, Otsuka Electronics, Japan). Measure-
ments were taken after diluting the nanoemulsion in water
and equilibrating at room temperature for at least 30 mi-
nutes prior to each measurement. All measurements were
taken at room temperature.
2.5. Cell viability assay
The cell viability was assessed by a modified MTT assay.
Cell viability was measured for the following three cell
lines: SKBR3, MCF-7, and MDA-MB 468 cells. These cell
lines were obtained from the American Type Culture
Collection (Rockville, MD). Human breast cancer cell
lines SKBR3, MCF-7, and MDA-MB 468 were grown
and maintained in each medium McCoy’s, MEM-α,
RPMI1640 supplemented with 10% heat inactivated
FBS, 50 IU ml−1 penicillin, and 50 μg ml−1 streptomycin,
respectively. Each cell was plated into a 96-well plate
(Corning Costar, Cambridge, MA) at 1 × 104 cells/well.
After incubation for 24 h, the medium was removed
and the prepared PFC/QDs nanoemulsions diluted to
Figure 1 A schematic representation of three different liquid PFC/QDs nanoemulsions (A) and their recognition of growth factor
receptor in breast cancer cells (B). The PFC core is surrounded by a lipid monolayer that is functionalized with DSPE-PEG3400-NHS to conjugate
with three different antibodies.
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Figure 2 Fluorescence spectra of the different three PFC/QDs nanoemulsions, excited at 390 nm. Narrow emission bands (31–35 nm
FWHM or full-width at half-maximum) indicate narrow particle size distributions.
Table 1 Summary of the optical and physicochemical







PFOB/QD525 525 31 233 −21.27
PFOB/QD606 606 35 230 −20.54
PFCE/QD606 603 31 227 −18.03
[a]Full-width at half maximum.
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200 μl ml−1) were poured into the wells. After another
24 h incubation period, the residual nanoemulsions were
removed and an MTT solution at a concentration of
2.5 mg ml−1 in magnesium- and calcium-free phosphate-
buffered saline was added to each well. The wells were
then incubated in a humidified CO2 incubator at 37°C for
1.5 h. 100 μl of acidified isopropanol/10% Triton X-100
solution was then added and the plates were shaken to
dissolve the formazan products. The absorbance at
570 nm was measured with a microplate reader (Bio-rad,
Hercules, CA) The cell survival rate in the control wells
without the PFC/QD solutions was considered as 100%
cell survival.
2.6. In vitro fluorescence and 19 F-MR imaging of breast
cancer cells
For fluorescence imaging, SKBR3, MCF-7, or MDA-MB
468 cells were incubated with 50 μl ml−1 antibody-
conjugated PFC/QD nanoemulsions (ErbB2-PFCE/QD606,
EGF1R-PFOB/QD525, IFG1R-PFOB/QD606) for 24 h at
37°C. After being washed with PBS, the labeled cells
were fixed with Cytofix/Cytoperm solution and stained
with DAPI in PBS. Fluorescence images were obtained
on a Deltavision RT deconvolution microscope (Applied
Precision Technologies, Issaquah, WA) using emission
filters (525WB20, 600WB20, Omega Optical, Brattleboro,
VT). All 19 F-MR imaging experiments of PFC/QD nanoe-
mulsions were performed with a 4.7 T Bruker scanner
(Biospec, Rheinstetten, Germany) using a double-tuned
1H/19F quadrature birdcage RF resonator. A 19 F-MR
image was captured with a FLASH sequence (128 × 128matrix; 30 × 30 mm2 FOV; 50 ms TR; 2.6 ms TE; 12 mm
slice thickness).
2.7. Statistical analysis
The statistical evaluations of the experiments were per-
formed by ANOVA analysis followed by a Newman-
Keuls multiple comparison test.
3 Results and discussion
We have fabricated multifunctional PFC/QD nanoemul-
sion particles for molecular imaging and targeted breast
cancer cells (Figure 1). The engineered PFC/QD nanoe-
mulsions are composed of two PFC materials (PFCE and
PFOB) and two different colored QDs (CdSe/ZnS 525,
606 nm). These nanoemulsions provide both 19 F-based
MR and optical imaging capabilities. To increase the
compatibility of hydrophobic QDs with PFC, tri-n-octyl-
phosphineoxide (TOPO) coated QDs were exchanged
with PFDT [26]. After vigorous stirring of the toluene-
PFC mixture, the CdSe/ZnS QDs migrated from the tolu-
ene phase to the PFC phase. For PFC liquids containing
CdSe/ZnS QDs to be useful as probes, for the examina-
tions of biological specimens, three different PFC/QD
Figure 3 19F MR and fluorescence imaging of PFC/QDs nanoemulsions: A) PFCE-resonance selective MR image, B) PFOB-resonance
selective MR image, C) image obtained by using a green filter, and D) image obtained by using a red filter.
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sions were emulsified in an aqueous solutions using sur-
factant mixtures. The fluorescence intensity and peak
wavelength of these nanoemulsions was measured using a
fluorescence spectrometer (Figure 2). The full-width-at-
half-maximum (FWHM) values of these nanoemulsions
are 31 – 35 nm, respectively. Because of their narrow and
symmetric emission spectra, high-quality PFC/QD nanoe-
mulsions are well suited to optical multiplexing. The zeta
potential and average size of different PFC/QD nanoemul-
sions were measured by dynamic light scattering analysis
(Table 1). To investigate the dual-mode imaging capabil-
ities of PFC/QD nanoemulsions, we measured a 19 F-MRFigure 4 Cell cytotoxicity for the different antibody-conjugated PFC/Q
24 h (A) and 48 h (B). Three different nanoemulsions are tested on the ceimage of specific PFC using a 4.7 T Bruker scanner
(Figure 3A,B) and an optical image of different color QDs
using suitable wavelength optical filters (Figure 3C,D). The
PFC/QD nanoemulsions containing two different PFC
liquids (PFCE or PFOB) are discriminated by using the
distinctly different spectrum of each PFC. These results
suggest that the PFC/QD nanoemulsions could serve as
more effective nanoprobes for the 19 F-MR imaging and
fluorescence imaging of various breast cancer cells.
We further investigated whether the PFC/QD nanoe-
mulsions could be used in targeted imaging of breast
cancer cells. The PFC/QD nanoemulsions were conjugated
with monoclonal antibodies that can target epidermalDs nanoemulsions and different cell types, incubated at 37°C for
ll viability for each cell type.
Figure 5 Luminescence (A-I) and 19 F MR (J-L) images of cultured SKBR3 (A, D, G, J), MDA-MB 468 (B, E, H, K), and MCF-7 (C, F, I, L) cells
as incubated with α-ErbB2-PFCE/QD606 (A-C, J), α-EGF1R-PFOB/QD525 (D-F, K) and α-IGF1R-PFOB/QD606 (G-I, L). The QDs (green and
red) and the DAPI-stained nuclei (blue) were recorded with Deltavision RT deconvolution microscope. The modified PFC/QDs nanoemulsions are
shown in green and red, and the DAPI-stained nuclei are shown in blue. Scale Bars: 10 μm.
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EGF1R (epidermal growth factor-1 receptor), ErbB2
(also called Her2 and Neu, epidermal growth factor-2
receptor), and IGF1R (insulin-like growth factor-1
receptor) (Figure 1B). These receptors are often overex-
pressed on the surface of human breast cancer cell lines
[SKBR3 (ErbB2-positive), MDA-MB 468 (EGF1R-positive),
MCF-7 (IGF1R-positive)] [27-29]. They serve as important
targets for selective cancer therapy. The expression or acti-
vation of human growth factor receptors are altered in
many epithelial tumours and clinical studies indicate that
they have important roles in tumour aetiology and pro-
gression. For targeting the breast cancer cells, three differ-
ent monoclonal antibodies (α-EGF1R, α-ErbB2, and
α-IGF1R) were reacted with NHS on the PFC/QD
nanoemulsions for 2 h at room temperature, respect-
ively. DSPE-PEG3400-NHS lipid which has a distal NHS
group at the end of PFC/QD nanoemulsions reacts with ahoming molecule. The homing molecules were conjugated
at the end of the lipid, and they specifically bind to their
receptors on the breast cancer cell surface. The antibody-
coated PFC/QD nanoemulsions purified by size-exclusion
chromatography with a sepharose 4B column and the
excess amount of antibodies were removed (Additional
file 1: Figure S1). We evaluated the cell damage caused by
the PFC/QDs nanoemulsions for biological applications.
We performed cell viability assay to determine the cyto-
toxicity of various PFC/QD nanoemulsions based on the
extracellular nanoemulsions exposure levels in cells
(Figure 4). Different doses (0, 2.5, 7.4, 22.2, 66.7,
200 μl ml−1) of these nanoemulsions were used for in vitro
cytotoxicity tests. We used three cell types: SKBR3 cell,
MCF-7 cell, and MDA-MB 468 cell for three PFC/QD
nanoemulsions. The result showed that no differences in
three type cells were observed for PFC/QD nanoemul-
sions at 24 h and 48 h. The tendencies of the cell viability
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same. Treatment of SKBR3 and MDA-MB 468 with 22.2 -
200 μl ml−1 of antibody-conjugated PFC/QD nanoemul-
sions significantly decreased the cell viability with respect
to control at 48 h. Within 48 h the cell viability in SKBR3
cells decreased from 92 ± 6% to 65 ± 7% at the α-ErbB2-
PFCE/QD606 concentration of 7.4 − 200 μl ml−1.
Also, for the α-EGF1R-PFOB/QD525 concentration of
2.5 − 200 μl ml−1 the viability of MDA-MB 468 cells
at 48 h decreased from 86 ± 3% to 49 ± 2%. There
were no significant changes in cell viability for these
nanoemulsions in MFC7 cells. Since QDs may slowly
release the toxic Cd2+ or Se2− ions into the solution, the
particles must be as inert as possible for any in vitro appli-
cation. The toxic of QDs not only depends on the concen-
tration of free Cd2+ ions but also depends on whether the
particles are ingested by a cell and where they are stored.
The release of Cd2+ from the particles’ surface can be re-
duced by employing core/shell particles or the coating of
the particles with silica, polymer, or liposome.
To investigate the targeting specificity, each breast
cancer cell line was incubated with three different
antibody-conjugated PFC/QD nanoemulsions (α-ErbB2-
PFCE/QD606, α-EGF1R-PFOB/QD525, and α-IGF1R-
PFOB/QD606). Fluorescence imagings were obtained
on a Deltavision RT deconvolution microscope. As shown
in Figure 4, the fluorescence of α-ErbB2-PFCE/QD606
nanoemulsions was only observed in the ErbB2-positive
SKBR3 breast cancer cells (Figure 5A). MDA-MB 468 and
MCF-7 cells showed only slight fluorescence signals
with α-ErbB2-PFCE/QD606 nanoemulsions (Figures 5B,C).
The attachment of α-ErbB2-PFCE/QD606 onto the SKBR3
cells suggests that there is a specific interaction between
the α-ErbB2 that bound to PFC/QDs and ErbB2. Also,
α-EGF1R-PFOB/QD525 and α-IGF1R-PFOB/QD606 nanoe-
mulsions were targeted to the MDA-MB 468 and MCF-7
cells, respectively (Figure 5D-I). Also, the 19 F-based MR im-
ages for the specific targeting of each antibody-conjugated
PFC/QD nanoemulsion in various breast cancer cells are
shown (Figure 5J-L). These results indicate that antibody-
PFC/QD nanoemulsions selectively bind to the target-
protein. Therefore, the modified PFC/QD can act as a
useful optical and 19 F-MR imaging agent for the diagnosis
and targeting of breast cancer cells.
4 Conclusion
In conclusion, the present study describes a novel ap-
proach for detecting the various breast cancer cells with
the antibody-conjugated PFC/QD nanoemulsions as a
type of bimodal imaging nanoprobe with unique MR
and optical imaging capabilities. It is believed that this
approach will provide a very promising tool for the diag-
nosis of breast cancer. Different PFC/QD nanoemulsions
can be conjugated to different antibodies, each targetedto specific proteins. The specific spectra of multiple
PFC/QD targeted to different tissue proteins can then be
simultaneously detected and quantified on one sample.
They also have enhanced photostability, allowing the
emission of fluorescent light over a length of time with-
out a brisk decrease in emission, and the strength of
their fluorescence means that low-level proteins can also
be detected, thereby increasing diagnostic sensitivity
[30-33]. PFC/QD nanoemulsions have great capacity as
an efficient nanoprobe for targeting breast cancer cells.
Furthermore, these nanoprobes have potential in a wider
variety of novel applications that are related to anti-
receptor therapy in cancer, molecular targeted approach,
and modulated drug delivery.
Additional file
Additional file 1: Figure S1. Gel permeation chromatogram of
antibody-conjugated PFC/QDs nanoemulsions. The antibody-conjugated
PFC/QDs nanoemulsions were separated by the sepharose 4B column.
▼, antibody-conjugated nanoemulsions; *, unreacted antibody.
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